This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
More treatments – and faster-acting treatments – for peanut allergies are urgently needed, and a new study outlines a promising drug technology based around a tiny nanoparticle just a few billionths of a meter in size. In tests on mice, the nanoparticle reversed peanut allergies and prevented them from developing in the first place.
The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.
British health officials recommended that people with severe allergy reactions not be given the vaccine. Such reactions to vaccines are rare, even in people who have allergies to food or bee stings.
Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England. billion last year, is also developing immunotherapies for other indications including egg and multi-tree nut allergies.
Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in the US.
For the 32 million individuals in the US with food allergies, more research into symptoms, causes, and treatments has been long sought after, but historically underfunded. per person being spent on food allergy research. Luckily for those with food allergies, the food allergy sector has benefitted from this influx of funding.
Patients who have digestive symptoms only after eating red meat may have developed an allergy caused by ticks. Previously, doctors looked for symptoms such as rashes, hives and breathing troubles. Image credit: Getty Images)
People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades.
On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes. | On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes.
ABATE Infection was supported within the NIH Collaboratory by the National Institute of Allergy and Infectious Diseases. Universal decolonization for all hospitalized adults in non-ICU settings was cost-effective in some scenarios. Read the full report. Learn more about ABATE Infection.
A new Nature Immunology study led by University of Pittsburgh and National Institutes of Health researchers sheds light on how a rare type of helper T cell, called Th9, can drive allergic disease, suggesting new precision medicine approaches to treating allergies in patients with high levels of Th9.
The food giant will pay French company Enterome about $40 million to join in the development of an inflammatory bowel disease drug as well as other food allergy treatments.
Peanut allergy (PA) is one of the most common food allergies that affect children in Western nations. Historically, the gold standard of the treatment for Peanut allergy constituted a strategic plan for peanut avoidance coupled with an adrenaline auto-injector (AAI) in case of contingencies.
According to the Asthma and Allergy Foundation of America, about 32 million people in the US have food allergies, which means allergy friendly food brands not only have a large audience base, but are also necessities. Partake Foods has become one of the most popular allergy friendly food brands and it recently secured $11.5
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
Having a latex allergy is no fun, but it can be a real challenge for health professionals who have to work with a wide variety of medical equipment that can contain the allergen.
Philip Li from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has pioneered a new nurse-led penicillin allergy triage and testing strategy—the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI), and demonstrated its effectiveness and safety compared to traditional allergy testing.
There have been many research efforts describing the nature and progression of dog allergies, but there have been very few applied studies that use this information to try to cure people of dog allergies entirely by artificially inducing immune tolerance.
The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.
Credit: William Anderegg If you live with seasonal allergies and feel like the pollen seasons feel longer and longer every year, you may be right. New research shows that pollen seasons start 20 days earlier, are 10 days longer, and feature 21% more pollen than in 1990–meaning more days of itchy, sneezy, drippy misery. Led […].
Children with food allergies might experience heightened anxiety over social situations involving food. A Baylor College of Medicine psychologist explains how parents can alleviate this stress while teaching them to be mindful of their allergies.
Their potential to suppress allergic reactions and offer new approaches to allergy treatment is particularly promising. The results indicate that -glucans can target the immune system and modulate pro-inflammatory responses. The research was published in the International Journal of Molecular Sciences.
Moncef Slaoui, co-head of the US government’s Operation Warp Speed COVID-19 vaccine programme, made the comments after the UK drugs regulator advised those with severe allergies to avoid the vaccine. The post Coronavirus vaccine may have allergy warning in US, says expert appeared first on.
who is on a mission to help parents save their children from food allergies by providing them with a powder added to their milk bottles. Zakowski started this company because his nephew developed several severe food allergies. Related: Red Meat Allergy Test Gets FDA Clearance. The product is part of a three-step guidance system.
The US Food and Drug Administration (FDA) has added sesame to its list of major allergens, making it easier for people with sesame allergies to safely consume packaged food without fear of an allergic reaction. Related: Top 3 Allergy Friendly Food Brands. percent of children and adults in the US are allergic to sesame.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content